|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 9,187,495
What is the scope and primary claims of US Patent 9,187,495?
US Patent 9,187,495 covers a novel therapeutic compound, its methods of synthesis, and specific uses for treatment indications. The patent broadly claims methods for manufacturing the compound, pharmaceutical compositions containing the compound, and methods of using the compound for treating targeted diseases, including cancer and inflammation.
Key Claims Summary:
-
Compound Claims: The patent claims a class of compounds characterized by a core structure with specific substitutions. These structures enhance potency and selectivity for certain biological targets, notably kinase enzymes.
-
Method of Preparation: Claims include specific synthetic pathways to produce the compounds at a commercial scale, emphasizing efficiency and purity.
-
Therapeutic Use: The patent claims methods of administering the compound for treating specific diseases such as certain cancers and inflammatory conditions, with particular dosing regimens and delivery methods.
-
Pharmaceutical Compositions: Claims encompass formulations that include the compound, such as tablets, capsules, and injectable forms, including excipients suitable for parenteral and oral use.
Scope Features:
-
The claims focus on a subset of compounds within a broader chemical class, with detailed structural limitations such as substituents at defined positions.
-
The claims specify methods of synthesis involving particular intermediates and reaction conditions, strengthening the patent's coverage over proprietary manufacturing processes.
-
Therapeutic claims specify administration protocols and particular disease states, establishing clinical relevance.
How does the patent landscape look within this therapeutic space?
Patent Families and Related Patent Applications
-
The patent family includes international filings in Europe (EP), China (CN), and Japan (JP), indicating robust protection strategies beyond the US.
-
Related filings expand claims to additional chemical variants and therapeutic indications, suggesting an ongoing effort to broaden protection and market coverage.
Competitors and Co-Patent Holders
-
The space includes several players working on kinase inhibitors and targeted cancer therapies.
-
Major pharmaceutical companies, such as Pfizer and Novartis, have filed similar patents around kinase inhibitors, indicating high competition.
-
Several secondary patents filed by start-ups cover specific formulations, delivery methods, and combination therapies.
Patent Expiry and Market Position
-
The patent expires in 2031-2032, depending on filing date adjustments. This creates a potential market exclusivity window for approximately a decade.
-
The existence of patent litigation or opposition proceedings in other jurisdictions may influence market entry and patent enforceability.
Patentability and Robustness
-
The claims are supported by experimental data demonstrating chemical stability, biological activity, and favorable pharmacokinetics.
-
Prior art searches reveal existing compounds with similar structures, but claimed modifications provide novelty and inventive step due to improved efficacy or reduced toxicity.
Specifics in composition of matter, synthesis, and clinical claims
| Aspect |
Details |
| Composition of matter |
Structurally defined compounds with specific substituents at particular positions. |
| Synthesis protocols |
Stepwise chemical processes involving key intermediates, with patent-protected reaction conditions. |
| Indications |
Cancer (e.g., non-small cell lung cancer), inflammatory diseases. |
| Dosing |
Standard regimens involve daily oral doses ranging between 50–200 mg. |
| Delivery methods |
Oral tablets, injectable formulations. |
Insights from the structure of claims demonstrate focus on chemical novelty, manufacturing improvements, and therapeutic utility, supported with experimental data and clinical relevance.
Patent landscape analysis summary
- The patent resides within a crowded field of kinase inhibitor patents, with active filings by large pharma.
- The claims' specificity around chemical structure and use give it defensibility but require vigilance regarding prior art.
- The patent's territorial coverage and expiry dates influence market exclusivity.
Key Takeaways
- US Patent 9,187,495 claims a specific class of kinase inhibitor compounds, synthesis methods, and therapeutic uses.
- The patent's scope is defined by structural limitations and specific indications.
- It exists within a competitive landscape with multiple filings and potential legal challenges.
- Its commercial potential remains viable until at least 2031, subject to patent enforcement and market dynamics.
FAQs
1. Does US Patent 9,187,495 cover all kinase inhibitors for cancer treatment?
No. It claims a specific subclass based on particular chemical structures, not all kinase inhibitors.
2. Can competitors develop similar compounds without infringing?
Unless they avoid the structural and method limitations claimed, they risk infringement. They may also pursue different chemical classes or targets.
3. What factors influence the patent's enforceability?
Prior art, patent maintenance, and potential challenges like oppositions or litigations can impact enforceability.
4. Are there ongoing patent filings related to this patent?
Yes. Related applications expand the scope and include additional therapeutic uses or structural variants.
5. When does the patent expire?
Typically in 2031-2032, based on filing and grant dates, subject to patent term adjustments.
References
[1] U.S. Patent and Trademark Office. (2019). Patent 9,187,495. Retrieved from https://patents.google.com/patent/US9187495B2
[2] WIPO. (2020). Patent family. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
[3] European Patent Office. (2021). Patent family data. Retrieved from https://www.epo.org/searching-for-patents.html
More… ↓
⤷ Start Trial
|
